40 search results for: coexisting diseases

Podcast

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis

15 min

Dermatology

Listen to the expert perspectives of Drs. Lisa Swanson and Weily Soong on clinical considerations in pediatric patients with atopic dermatitis.

expert video

Differences in Itch in AD, PN, and CSU

2 min

Dermatology

Dr. Shawn Kwatra reviews the distinct characteristics of itch, and the associated patient burden in AD, PN, and CSU.

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

2 min

Dermatology

Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

expert video

Shared and Unique Characteristics of AD, PN, and CSU

17 min

Dermatology

Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

expert video

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

20 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

expert video

Itch in AD, PN and CSU: Role of Type 2 Inflammation

27 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

expert video

Can advanced systemic therapies modify pathomechanisms in AD?

5 min

Dermatology

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

expert video

Can early intervention modify the course of AD?

5 min

Dermatology

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

expert video

Trajectories of Type 2 Inflammation in Pediatric Patients

43 min

Type 2 Inflammation

Drs. Jonathan Spergel, Wanda Phipatanakul, Eric Simpson, Prof. Salvatore Oliva discuss pediatric patient/caregiver burden and multidisciplinary care

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region